Tlhaloso
Foromo ea molek'hule ea karolo ena e bohareng ke C13H10ClN3O2S, 'me boima ba eona ba molek'hule ke 307.755.Sebopeho sa eona se nepahetseng sa limolek'hule se nolofalletsa tlhahiso e sebetsang hantle le e phahameng ea tofacitinib.Ka hona, tofacitinib intermediate 1,4-chloro-7-p-toluenesulfonyl-7H pyrrolo [2,3-d] pyrimidine ke karolo ea bohlokoa indastering ea meriana ho fana ka phekolo e sebetsang bakeng sa maloetse a ikemetseng.
Lihlahisoa tsa rona li etsoa ho sebelisoa mekhoa ea morao-rao ho netefatsa boleng bo phahameng ka ho fetisisa le bo tsitsitseng.Re utloisisa bohlokoa ba ho ba le li-intermediate tse tšepahalang le tse hloekileng tlhahisong ea meriana, ke ka lebaka leo re ikemiselitseng ho boloka litekanyetso tse thata ka ho fetisisa nakong ea tlhahiso ea rona.Tofacitinib ea rona ea mahareng 1,4-chloro-7-p-toluenesulfonyl-7H pyrrolo[2,3-d]pyrimidine e etsa tlhahlobo e matla ea bohloeki, botsitso le polokeho ho lumella bareki ba rona ho ba le kholiseho ea ho ts'epahala ha motsoako o moholo oa tofacitinib.
Khetha Rona
JDK e na le lisebelisoa tsa tlhahiso ea maemo a pele le lisebelisoa tsa taolo ea boleng, tse netefatsang phepelo e tsitsitseng ea li-intermediate tsa API.Sehlopha sa litsebi se tiisetsa R&D ka sehlahisoa.Khahlanong le bobeli, re batla CMO & CDMO 'marakeng oa lapeng le oa machabeng.